405 related articles for article (PubMed ID: 22753230)
1. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract][Full Text] [Related]
2. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.
McBride SM; Perez DA; Polley MY; Vandenberg SR; Smith JS; Zheng S; Lamborn KR; Wiencke JK; Chang SM; Prados MD; Berger MS; Stokoe D; Haas-Kogan DA
J Neurooncol; 2010 Mar; 97(1):33-40. PubMed ID: 19705067
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
[TBL] [Abstract][Full Text] [Related]
4. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.
Park S; Zhao D; Hatanpaa KJ; Mickey BE; Saha D; Boothman DA; Story MD; Wong ET; Burma S; Georgescu MM; Rangnekar VM; Chauncey SS; Habib AA
Cancer Res; 2009 May; 69(10):4107-11. PubMed ID: 19435890
[TBL] [Abstract][Full Text] [Related]
5. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
Wiencke JK; Zheng S; Jelluma N; Tihan T; Vandenberg S; Tamgüney T; Baumber R; Parsons R; Lamborn KR; Berger MS; Wrensch MR; Haas-Kogan DA; Stokoe D
Neuro Oncol; 2007 Jul; 9(3):271-9. PubMed ID: 17504928
[TBL] [Abstract][Full Text] [Related]
6. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
7. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation.
Peterziel H; Müller J; Danner A; Barbus S; Liu HK; Radlwimmer B; Pietsch T; Lichter P; Schütz G; Hess J; Angel P
Neuro Oncol; 2012 Apr; 14(4):426-39. PubMed ID: 22394497
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction molecules in gliomas of all grades.
Ermoian RP; Kaprealian T; Lamborn KR; Yang X; Jelluma N; Arvold ND; Zeidman R; Berger MS; Stokoe D; Haas-Kogan DA
J Neurooncol; 2009 Jan; 91(1):19-26. PubMed ID: 18759130
[TBL] [Abstract][Full Text] [Related]
9. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
11. MiR-17 targets PTEN and facilitates glial scar formation after spinal cord injuries via the PI3K/Akt/mTOR pathway.
Luan Y; Chen M; Zhou L
Brain Res Bull; 2017 Jan; 128():68-75. PubMed ID: 27693649
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
[TBL] [Abstract][Full Text] [Related]
14. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.
Negishi Y; Miya F; Hattori A; Johmura Y; Nakagawa M; Ando N; Hori I; Togawa T; Aoyama K; Ohashi K; Fukumura S; Mizuno S; Umemura A; Kishimoto Y; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Nakanishi M; Saitoh S
BMC Med Genet; 2017 Jan; 18(1):4. PubMed ID: 28086757
[TBL] [Abstract][Full Text] [Related]
15. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
Mohamed E; Kumar A; Zhang Y; Wang AS; Chen K; Lim Y; Shai A; Taylor JW; Clarke J; Hilz S; Berger MS; Solomon DA; Costello JF; Molinaro AM; Phillips JJ
Neuro Oncol; 2022 Sep; 24(9):1471-1481. PubMed ID: 35287169
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
17. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
18. MAGI3 Suppresses Glioma Cell Proliferation via Upregulation of PTEN Expression.
Ma Q; Zhang Y; Meng R; Xie KM; Xiong Y; Lin S; He ZL; Tao T; Yang Y; Zhao JZ; He JQ
Biomed Environ Sci; 2015 Jul; 28(7):502-9. PubMed ID: 26248734
[TBL] [Abstract][Full Text] [Related]
19. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma.
Waldron JS; Yang I; Han S; Tihan T; Sughrue ME; Mills SA; Pieper RO; Parsa AT
J Clin Neurosci; 2010 Dec; 17(12):1543-7. PubMed ID: 20822910
[TBL] [Abstract][Full Text] [Related]
20. TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway.
Gao X; Jiang W; Ke Z; Huang Q; Chen L; Zhang G; Li C; Yu X
Biochem Biophys Res Commun; 2022 Jan; 586():34-41. PubMed ID: 34826698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
